Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Craddock

Showing results (61-70 of 165) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|February 3, 2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaRakesh Popat, Heather Oakervee, Catherine Williams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow TransplantationGordon Cook, Graeme M Smith, Keiren Kirkland, et al.
Cancer Discovery|October 11, 2022
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future DirectionsNaval G Daver, Abhishek Maiti, Tapan M Kadia, et al.
British Journal of Haematology|September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapyJustin Loke, Marlen Metzner, Rebecca Boucher, et al.
Bone Marrow Transplantation|August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trialRam Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry studyAndrew D Chantry, John A Snowden, Charles Craddock, et al.
Leukemia|June 18, 2024
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillanceNicholas McCarthy, Gege Gui, Florent Dumezy, et al.
Haematologica|August 20, 2016
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantationPaul Ferguson, Robert K Hills, Angela Grech, et al.
Blood Advances|July 19, 2024
CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHDKriti Verma, Wayne Croft, Sandra Margielewska-Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaCharles Craddock, Daniel Slade, Carmela De Santo, et al.
Pageof 17

Showing results (61-70 of 165) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|February 3, 2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaRakesh Popat, Heather Oakervee, Catherine Williams, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 20, 2010
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow TransplantationGordon Cook, Graeme M Smith, Keiren Kirkland, et al.
Cancer Discovery|October 11, 2022
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future DirectionsNaval G Daver, Abhishek Maiti, Tapan M Kadia, et al.
British Journal of Haematology|September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapyJustin Loke, Marlen Metzner, Rebecca Boucher, et al.
Bone Marrow Transplantation|August 27, 2021
Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trialRam Malladi, Ikhlaaq Ahmed, Graham McIlroy, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2006
Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry studyAndrew D Chantry, John A Snowden, Charles Craddock, et al.
Leukemia|June 18, 2024
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillanceNicholas McCarthy, Gege Gui, Florent Dumezy, et al.
Haematologica|August 20, 2016
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantationPaul Ferguson, Robert K Hills, Angela Grech, et al.
Blood Advances|July 19, 2024
CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHDKriti Verma, Wayne Croft, Sandra Margielewska-Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid LeukemiaCharles Craddock, Daniel Slade, Carmela De Santo, et al.
Pageof 17